A Study to the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
Summary
- Eligibility
- for people ages 2-16 (full criteria)
- Location
- at Oakland, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Paul Harmatz, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Paul Harmatz, MD
Professor, Pediatrics, School of Medicine. Authored (or co-authored) 203 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Denali Therapeutics Inc.
- ID
- NCT05371613
- Phase
- Phase 2/3 research study
- Study Type
- Interventional
- Participants
- Expecting 54 study participants
- Last Updated